X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (405) 405
Patent (109) 109
Conference Proceeding (14) 14
Publication (9) 9
Book Chapter (2) 2
Book Review (1) 1
Dissertation (1) 1
Technical Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (119) 119
index medicus (102) 102
male (101) 101
female (94) 94
oncology (85) 85
aged (75) 75
middle aged (67) 67
chemotherapy (62) 62
cancer (57) 57
adult (56) 56
medicine & public health (49) 49
metastasis (41) 41
chemistry (40) 40
care and treatment (38) 38
human necessities (37) 37
metallurgy (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
colorectal cancer (35) 35
physics (35) 35
research (34) 34
analysis (33) 33
animals (32) 32
edible oils or fats, e.g. margarines, shortenings, cookingoils (32) 32
electricity (32) 32
foods or foodstuffs (32) 32
their treatment, not covered by other classes (32) 32
cancer research (31) 31
foods, foodstuffs, or non-alcoholic beverages, not covered bysubclasses a23b - a23j (31) 31
preservation of foods or foodstuffs, in general (31) 31
their preparation or treatment, e.g. cooking, modification ofnutritive qualities, physical treatment (31) 31
basic electric elements (29) 29
gastric cancer (29) 29
antimitotic agents (28) 28
antineoplastic agents (28) 28
drug combinations (28) 28
s-1 (27) 27
treatment outcome (26) 26
aged, 80 and over (25) 25
stomach cancer (25) 25
stomach neoplasms - drug therapy (25) 25
hygiene (24) 24
medical or veterinary science (24) 24
oxaliplatin (24) 24
preparations for medical, dental, or toilet purposes (24) 24
survival (24) 24
oncology, experimental (23) 23
patients (23) 23
surgical oncology (23) 23
tegafur - administration & dosage (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
disease-free survival (22) 22
mice (22) 22
stomach neoplasms - pathology (22) 22
cisplatin - administration & dosage (21) 21
calculating (20) 20
clinical trials (20) 20
computing (20) 20
counting (20) 20
oxonic acid - administration & dosage (20) 20
performing operations (20) 20
pharmacology & pharmacy (20) 20
surgery (20) 20
transporting (20) 20
trial (20) 20
cisplatin (19) 19
colorectal neoplasms - drug therapy (19) 19
gastroenterology & hepatology (19) 19
therapy (19) 19
acyclic, carbocyclic or heterocyclic compounds containingelements other than carbon, hydrogen, halogen, oxygen, nitrogen,sulfur, selenium or tellurium (18) 18
blasting (18) 18
cancer patients (18) 18
electric digital data processing (18) 18
fodder (18) 18
heating (18) 18
lighting (18) 18
mechanical engineering (18) 18
organic chemistry (18) 18
phosphatide compositions for foodstuffs (18) 18
protein compositions for foodstuffs (18) 18
weapons (18) 18
working-up proteins for foodstuffs (18) 18
animal and vegetable oils, fats, fatty substances and waxes (17) 17
candles (17) 17
detergents (17) 17
essential oils (17) 17
fatty acids therefrom (17) 17
japan (17) 17
perfumes (17) 17
producing, refining and preservingfats, fatty substances (17) 17
bevacizumab (16) 16
colorectal neoplasms - pathology (16) 16
fluorouracil (16) 16
original (16) 16
prognosis (16) 16
5-fluorouracil (15) 15
drug administration schedule (15) 15
cancer therapies (14) 14
gastroenterology (14) 14
irinotecan (14) 14
medical prognosis (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (500) 500
Japanese (37) 37
French (26) 26
German (22) 22
Chinese (10) 10
Korean (3) 3
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 2/2018, Volume 23, Issue 1, pp. 1 - 34
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Cancer Science, ISSN 1347-9032, 07/2014, Volume 105, Issue 7, pp. 812 - 817
This multicenter phase II study first investigated the efficacy and safety of nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) when given every 3 weeks... 
phase II | triweekly | Gastric cancer | nab‐paclitaxel | second‐line chemotherapy | Second-line chemotherapy | nab-paclitaxel | Phase II | Triweekly | PLUS CISPLATIN | CREMOPHOR-FREE | second-line chemotherapy | ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE | SALVAGE CHEMOTHERAPY | SUPPORTIVE CARE | ONCOLOGY | COMPARING IRINOTECAN | COMBINATION CHEMOTHERAPY | 1ST-LINE THERAPY | SOLVENT-BASED PACLITAXEL | Humans | Middle Aged | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Paclitaxel - adverse effects | Male | Stomach Neoplasms - pathology | Treatment Outcome | Stomach Neoplasms - drug therapy | Paclitaxel - therapeutic use | Albumins - therapeutic use | Disease-Free Survival | Antineoplastic Agents, Phytogenic - administration & dosage | Albumins - adverse effects | Leukopenia - chemically induced | Adult | Female | Aged | Antineoplastic Agents, Phytogenic - therapeutic use | Neutropenia - chemically induced | Stomach Neoplasms - mortality | Antineoplastic Agents, Phytogenic - adverse effects | Antimitotic agents | Relapse | Chemotherapy | Clinical trials | Albumin | Product development | Antineoplastic agents | Stomach cancer | Diseases | Cancer | Breast cancer | Metastasis | Neuropathy | Cancer therapies | Disease control | Survival | Blood | Nanoparticles | Lymphopenia | Paclitaxel | Drug dosages | Neutropenia | Pharmaceuticals | Index Medicus | Original
Journal Article
Electrochimica Acta, ISSN 0013-4686, 02/2011, Volume 56, Issue 5, pp. 2009 - 2016
The electrocatalytic activity of amorphous and crystalline RuO thin films for oxygen evolution in an aqueous solution was investigated. The RuO films were... 
Oxygen evolution | RuO2 | Amorphous | Distortion | Electrocatalytic activity | RuO | ELECTROCHEMISTRY | ATOMICALLY SMOOTH | RAMAN-SPECTROSCOPY | NANOCRYSTALLINE RUO2 | CATALYST | HYDROUS RUTHENIUM OXIDE | PARTICLE-SIZE DEPENDENCE | SURFACE | METAL | ISOTACTIC POLYPROPYLENE | WATER
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Cancer Science, ISSN 1347-9032, 08/2012, Volume 103, Issue 8, pp. 1502 - 1507
Journal Article
Gastric Cancer, ISSN 1436-3291, 7/2016, Volume 19, Issue 3, pp. 968 - 976
Journal Article
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 2/2014, Volume 140, Issue 2, pp. 319 - 328
Journal Article